Life Sciences a ‘Top Priority’ for Agilent As Firm Considers M&A Options, CEO Says

Bill Sullivan said Agilent remains on the lookout for acquisition targets, and that the firm’s “top priority continues to be in the life-sciences area, and we will continue to look for opportunities that we believe will drive value for shareholders.”

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.